Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences
Werte in diesem Artikel
WASHINGTON, Aug. 28, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in September 2025:
The Cantor Global Healthcare Conference 2025 in New York City on Wednesday, September 3, 2025. A corporate presentation is scheduled for 3:55 p.m. Eastern Time.
The 2025 Wells Fargo Healthcare Conference in Boston on Thursday, September 4, 2025. A corporate presentation is scheduled for 4:30 p.m. Eastern Time.
The H.C. Wainwright Annual Global Investment Conference in New York City on Tuesday, September 9, 2025. A corporate presentation is scheduled for 8:30 a.m. Eastern Time.
The corporate presentations given at the Cantor, Wells Fargo and H.C. Wainwright conferences may be accessed live on Vanda's corporate website, www.vandapharma.com. Investors should click on the Investors tab and follow the link under Recent Events. Investors are advised to go to the conference website at least 15 minutes early to register, download, and install any necessary software or presentations. A link to the archived conference will be available on Vanda's website for a period of approximately 30 days.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-participation-at-september-2025-investor-conferences-302541540.html
SOURCE Vanda Pharmaceuticals Inc.
Übrigens: Vanda Pharmaceuticals und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf Vanda Pharmaceuticals
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Vanda Pharmaceuticals
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Vanda Pharmaceuticals IncShs
Analysen zu Vanda Pharmaceuticals IncShs
Datum | Rating | Analyst | |
---|---|---|---|
11.12.2018 | Vanda Pharmaceuticals Perform | Oppenheimer & Co. Inc. | |
04.12.2018 | Vanda Pharmaceuticals Overweight | Cantor Fitzgerald | |
21.09.2018 | Vanda Pharmaceuticals Outperform | Oppenheimer & Co. Inc. | |
19.01.2018 | Vanda Pharmaceuticals Buy | Seaport Global Securities | |
26.05.2017 | Vanda Pharmaceuticals Buy | H.C. Wainwright & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
04.12.2018 | Vanda Pharmaceuticals Overweight | Cantor Fitzgerald | |
21.09.2018 | Vanda Pharmaceuticals Outperform | Oppenheimer & Co. Inc. | |
19.01.2018 | Vanda Pharmaceuticals Buy | Seaport Global Securities | |
26.05.2017 | Vanda Pharmaceuticals Buy | H.C. Wainwright & Co. | |
09.11.2016 | Vanda Pharmaceuticals Buy | Aegis Capital |
Datum | Rating | Analyst | |
---|---|---|---|
11.12.2018 | Vanda Pharmaceuticals Perform | Oppenheimer & Co. Inc. | |
30.07.2008 | Vanda Pharmaceuticals Downgrade | Banc of America Securities LLC | |
29.07.2008 | Vanda Pharmaceuticals Downgrade | JP Morgan Chase & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Vanda Pharmaceuticals IncShs nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen